

Dipeptidyl Peptidase (DPP-4) Inhibitors

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Strength	Quantity Limit
Januvia (sitagliptin)	25 mg 50 mg 100 mg	May be subject to quantity limit
alogliptin	6.25 mg 12.5 mg 25 mg	
Onglyza (saxagliptin)	2.5 mg 5 mg	
Janumet (sitagliptin/metformin)	50-500 mg 50-1000 mg	
Janumet XR (sitagliptin/metformin)	50mg-500mg 50mg-1000mg 100mg-1000mg	

APPROVAL CRITERIA

Requests for a **preferred** DPP-4 inhibitor (Januvia, Janumet, Janumet XR) may be approved when the following criteria are met:

- I. Individual has had a trial and inadequate response or intolerance to metformin (AAACE/ACE 2020). Medication samples/coupons/discount cards are excluded from consideration as a trial); **OR**
- II. Individual has a contraindication to metformin therapy.

Requests for a **non-preferred** DPP-4 inhibitor (Onglyza, alogliptin) may be approved when the following criteria are met:

- I. One of the following:
 - a. Individual has had a trial and inadequate response or intolerance to metformin Medication samples/coupons/discount cards are excluded from consideration as a trial); **OR**
 - b. Individual has a contraindication to metformin therapy.

AND

- II. Documentation is provided that individual has had a trial and inadequate response or intolerance to one preferred DPP-4 inhibitor (Januvia, Janumet, Janumet XR). Medication samples/coupons/discount cards are excluded from consideration as a trial);

Requests for a DPP-4 inhibitor may not be approved for the following:

- I. Individual is using in combination with a GLP-1 receptor agonist (including but not limited to Saxenda, Wegovy, Adlyxin, Bydureon BCise, Byetta, Ozempic, Rybelsus, Trulicity, Victoza, Mounjaro, Soliqua or Xultophy).

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: May 9, 2023.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
4. Samson SL, Vellanki P, Blonde L, et. al. American Association of Clinical Endocrinologists (AACE) Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update. *Endocrine Practice*. 2023;29:305-340.
5. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Last updated: November 14, 2017. Available at <https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm>. Accessed: May 9, 2023.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.